VaxArray potency assay for rapid assessment of “pandemic” influenza vaccines
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2059-0105
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
VaxArray potency assay for rapid assessment of “pandemic” influenza vaccines ; volume:3 ; number:1 ; day:8 ; month:10 ; year:2018 ; pages:1-11 ; date:12.2018
npj vaccines ; 3, Heft 1 (8.10.2018), 1-11, 12.2018
- Urheber
-
Byrne-Nash, Rose T.
- Beteiligte Personen und Organisationen
-
Miller, David F.
Bueter, Katie M.
Gillis, Jacob H.
Kuck, Laura R.
Rowlen, Kathy L.
SpringerLink (Online service)
- DOI
-
10.1038/s41541-018-0080-6
- URN
-
urn:nbn:de:101:1-2018102020390671197643
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Byrne-Nash, Rose T.
- Miller, David F.
- Bueter, Katie M.
- Gillis, Jacob H.
- Kuck, Laura R.
- Rowlen, Kathy L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines
Vaccines for pandemic influenza
Influenza vaccines for the future
Better influenza vaccines: an industry perspective
Development of a potency assay for CD34+ cell-based therapy
Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency
In vitro CAR-T cell killing: validation of the potency assay
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
Cell membrane array fabrication and assay technology
Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines
Factors affecting the immunogenicity of influenza vaccines in human
Cell-Based Reporter Release Assay to Determine the Potency of Proteolytic Bacterial Neurotoxins
A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines
Vaccines for pandemic influenza
Influenza vaccines for the future
Better influenza vaccines: an industry perspective
Development of a potency assay for CD34+ cell-based therapy
Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency
In vitro CAR-T cell killing: validation of the potency assay
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
Cell membrane array fabrication and assay technology
Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines
Factors affecting the immunogenicity of influenza vaccines in human
Cell-Based Reporter Release Assay to Determine the Potency of Proteolytic Bacterial Neurotoxins
A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines
Vaccines for pandemic influenza
Influenza vaccines for the future
Better influenza vaccines: an industry perspective
Development of a potency assay for CD34+ cell-based therapy
Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency
In vitro CAR-T cell killing: validation of the potency assay
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
Cell membrane array fabrication and assay technology
Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines
Factors affecting the immunogenicity of influenza vaccines in human